Thermo Fisher Scientific Inc. (TMO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Thermo Fisher's earnings call highlights strong financial performance, with increased revenue and EPS guidance for 2025 and expected organic growth acceleration in 2026-2027. Strategic M&A, cost management, and improved tariff situations are positive factors. The Q&A session reinforced confidence in growth, despite challenges in China. The overall sentiment is positive due to optimistic guidance and strategic initiatives, suggesting a likely stock price increase in the coming weeks.
Key Financial Performance
Revenue Revenue grew 5% year-over-year to $11.12 billion. This growth was driven by strong execution, operational performance, and contributions from acquisitions and foreign exchange.
Adjusted Operating Income Adjusted operating income grew 9% year-over-year to $2.59 billion. This increase was attributed to strong productivity, volume leverage, and active cost management.
Adjusted Operating Margin Adjusted operating margin expanded by 100 basis points year-over-year to 23.3%. This improvement was due to strong productivity and operational efficiency.
Adjusted EPS Adjusted EPS grew 10% year-over-year to $5.79 per share. This growth was driven by strong operational performance and productivity.
Life Sciences Solutions Revenue Revenue in this segment increased 8% year-over-year, with 5% organic growth. Growth was led by the Bioproduction business, which had excellent performance.
Analytical Instruments Revenue Revenue in this segment increased 5% year-over-year, with 4% organic growth. Growth was led by electron microscopy and chromatography and mass spectrometry businesses.
Specialty Diagnostics Revenue Revenue in this segment grew 4% year-over-year, with 2% organic growth. Growth was led by Transplant Diagnostics and Immunodiagnostics businesses.
Laboratory Products and Biopharma Services Revenue Revenue in this segment increased 4% year-over-year, with 3% organic growth. Growth was led by the Research and Safety market channel.
Free Cash Flow Year-to-date free cash flow was $3.3 billion after investing $1 billion in net capital expenditures. This reflects strong cash generation and disciplined capital deployment.
Adjusted Gross Margin Adjusted gross margin was 41.9%, a 10 basis point increase year-over-year. This was driven by strong productivity and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Clinical Next-Gen Sequencing: Expanded offerings, including FDA-approved Oncomine Dx Express Test for non-small cell lung cancer and broader tumor profiling applications.
Proteomics: Launched Olink Target 48 Neurodegeneration panel for research into Alzheimer's, Parkinson's, and Multiple Sclerosis.
Analytical Instruments: Introduced two new electron microscopes (Talos 12 and Scios 3) and Chromeleon 7.4 software for chromatography and mass spectrometry workflows.
Pharma and Biotech: Mid-single-digit growth led by Bioproduction and Analytical Instruments businesses.
Industrial and Applied: Mid-single-digit growth driven by Electron Microscopy and research and safety market channel.
Diagnostics and Healthcare: Revenue growth improved over Q2 but remained down low single digits due to conditions in China.
Operational Performance: Revenue grew 5% to $11.12 billion, adjusted operating income grew 9% to $2.59 billion, and adjusted EPS grew 10% to $5.79.
PPI Business System: Enabled cost management and strong earnings growth, with plans to integrate OpenAI for further productivity improvements.
OpenAI Collaboration: Focused on embedding AI into products and operations to improve clinical research and productivity.
AstraZeneca Partnership: Collaborative R&D projects in chromatography, molecular genomics, and proteomics.
Acquisitions: Acquired Filtration and Separation business from Solventum and sterile fill-finish site from Sanofi to expand bioprocessing and U.S. drug manufacturing capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue decline in academic and government markets: Revenue in this segment declined in the low single digits, with conditions in the U.S. remaining similar to the previous quarter. This indicates ongoing challenges in this market segment.
Diagnostics and Healthcare revenue decline: Revenue in this segment remained down in the low single digits, largely due to conditions in China, highlighting regional economic or operational challenges.
Impact of tariffs and related FX: The company faced a $0.11 EPS impact from tariffs and related foreign exchange, which continues to create volatility and pressure on margins.
China market performance: China experienced a mid-single-digit revenue decline, reflecting challenges in this key market.
Unfavorable mix in Analytical Instruments segment: The Analytical Instruments segment experienced a 230 basis point decline in adjusted operating margin, driven by unfavorable mix and the impact of tariffs and FX.
Pandemic-related revenue runoff: The Laboratory Products and Biopharma Services segment faced a 1% revenue headwind due to the runoff of pandemic-related revenue, indicating a lingering impact from the pandemic.
Dilution from recent acquisitions: The company experienced a $0.05 EPS dilution from recent acquisitions, which may temporarily impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Thermo Fisher Scientific has raised its 2025 full-year revenue guidance to a range of $44.1 billion to $44.5 billion, reflecting an increase of $420 million from the prior guidance. Organic revenue growth at the midpoint of the guide remains at 2%, including a 1% headwind from the runoff of pandemic-related revenue.
Adjusted EPS Guidance: The company has increased its adjusted EPS guidance for 2025 to a range of $22.60 to $22.86, reflecting a $0.20 increase at the midpoint compared to the prior guidance. This includes a $0.05 dilution from recent acquisitions.
Adjusted Operating Margin: The adjusted operating margin for 2025 is now expected to be in the range of 22.7% to 22.8%, reflecting a 20 basis point improvement from the prior guidance.
Capital Deployment: Thermo Fisher plans to deploy $7.6 billion of capital in 2025, including $4 billion for recently closed acquisitions, $3 billion for share buybacks, and $600 million for dividends.
Free Cash Flow: The company expects approximately $7 billion in free cash flow for 2025.
Foreign Exchange Impact: FX is expected to be a year-over-year tailwind to revenue of $230 million but a headwind to adjusted operating income and adjusted EPS of $110 million and $0.37, respectively.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid in Q3: $160 million of capital returned to shareholders through dividends.
Share repurchase in Q3: $1 billion of shares repurchased during the quarter.
Total share repurchase in 2025: $3 billion of shares repurchased for the year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What has changed in conversations with major customers regarding reshoring and how would Thermo Fisher benefit?
A:Marc Casper noted that there is excitement around scientific breakthroughs and confidence in customer pipelines. Customers are navigating government policies effectively, leading to announcements on pricing and reshoring activities in the U.S. Thermo Fisher is actively engaged in helping customers with new sites and expansions, which will benefit their channel business, Bioproduction, and Analytical Instruments. However, new construction projects will take time, with significant benefits expected around 2027-2028. More immediate benefits come from leveraging their Pharma Services network, including their sterile fill-finish capabilities and the recent acquisition of a Sanofi site in the U.S.
Q:What is the update on academic and government funding and the impact of the government shutdown?
A:Marc Casper stated that academic and government funding showed slight improvement in Europe, while the U.S. and China remained similar to Q2. Customers in the U.S. feel better about a stable funding environment, with expectations of a flat NIH budget. The government shutdown adds uncertainty and delays expenditures, but Thermo Fisher has accounted for this in their Q4 guidance and feels well-positioned to navigate it.
Q:What drove the strength in the Analytical Instruments business, and what is the outlook for the segment?
A:The strength in Analytical Instruments was driven by innovation in mass spectrometry and cryo-electron microscopy, which were well adopted by customers. Chromatography and mass spectrometry were key drivers, while the chemical analysis business faced headwinds. The segment delivered mid-single-digit growth in Q3. For Q4, a stronger comparison from the previous year is expected to impact growth, but the underlying health of the business remains strong.
Q:What is the impact of the pricing and reimbursement environment in China on Specialty Diagnostics?
A:Specialty Diagnostics faced weak conditions in China due to pricing and reimbursement pressures, but this was expected. Thermo Fisher has a smaller presence in the Chinese diagnostics market compared to peers. The business saw slight improvement compared to the prior quarter, and the overall impact on Thermo Fisher is modest.
Q:What are the latest thoughts on the 2026 outlook and progression towards 3%-6% organic growth?
A:Marc Casper expressed confidence in achieving 3%-6% organic growth over the next few years, supported by strong operating margin growth. Current organic growth is at 2%, with a 1% headwind from COVID runoff that will not repeat next year. Stabilization in academic and government funding and China, along with share gains and market improvements, are expected to drive growth further into the range.
Q:What is the update on the Clinical Research business and new authorizations?
A:The Clinical Research business showed strong progression, with revenue growth stepping up to low single digits in Q3. Authorizations were well ahead of revenue growth, positioning the business for future growth. Thermo Fisher is innovating in clinical research, including the Accelerated Drug Development program and an OpenAI collaboration to improve trial efficiency and data utilization.
Q:What is the demand trend from smaller emerging biotech companies?
A:Demand from smaller emerging biotech companies showed improvement in Q3, with strong momentum in Clinical Research and early activities in Pharma Services. M&A activity by large pharma acquiring biotech is also helping the ecosystem and driving reinvestment.
Q:What is the impact of pricing initiatives in China on research and industrial markets?
A:Pricing initiatives in China have less impact on research and industrial markets compared to diagnostics. Academic and government funding in China benefits from stimulus programs but remains pressured. Pharma and Biotech grew modestly in Q3, and the overall decline in China was mid-single digits, an improvement from Q2.
Q:What is the potential impact of onshoring announcements on Thermo Fisher's business?
A:Onshoring announcements are expected to generate incremental demand for new equipment, initial stocking inventory, and new labs over the next few years. While drug volumes remain unchanged, Thermo Fisher's strong presence in Bioproduction positions it to benefit from these activities. The impact will be more pronounced in the medium term, with greenfield projects expected around 2027 and beyond.
Q:What is the financial impact of recent tariff changes and acquisitions?
A:Tariff changes provided an $0.11 pickup in Q3, with no significant changes expected in Q4. Recent acquisitions, including the Filtration and Separation business and the Sanofi site, are expected to be slightly dilutive in the short term but accretive in the long term as integration costs subside and revenue builds.
Q:What is the update on the Accelerated Drug Development program and its adoption?
A:The Accelerated Drug Development program has gained strong adoption, particularly among biotech companies that outsource most of their work. The program helps streamline drug development by integrating clinical research and Pharma Services, reducing time and cost for customers. Large pharma companies have also shown interest, driving share gains for Thermo Fisher.
Q:What is the outlook for Thermo Fisher's growth and performance in 2026 and beyond?
A:Thermo Fisher expects growth to build over the next few years, with organic growth accelerating from the current 2% to the 3%-6% range. Stabilization in key markets, share gains, and operational execution are expected to drive strong earnings growth and set the company up for continued success in 2026 and beyond.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers or detailed quantifications for the potential financial impact of onshoring activities, the exact size of incremental demand from new facilities, and the total impact of pricing dynamics in China. Additionally, while they expressed confidence in achieving 3%-6% organic growth, they did not provide detailed breakdowns or timelines for specific segments contributing to this growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AstraZeneca
Diagnostics
FX tailwind
Filtration Separation
Life
OpenAI
PPI
Sanofi
acquisition Filtration
basis point
beat
capability
capital acquisition
capital deployment
cash flow
chromatography
collaboration
detail
development
digit
dilution
drug
electron
income
increase
investment
lab
line
margin basis
midpoint guide
patient
productivity
research
segment
tariff FX
TMO Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Thermo Fisher Scientific Inc. (TMO) Q3 2025 Earnings Call Transcript
Positive10-22
Thermo Fisher's earnings call highlights strong financial performance, with increased revenue and EPS guidance for 2025 and expected organic growth acceleration in 2026-2027. Strategic M&A, cost management, and improved tariff situations are positive factors. The Q&A session reinforced confidence in growth, despite challenges in China. The overall sentiment is positive due to optimistic guidance and strategic initiatives, suggesting a likely stock price increase in the coming weeks.
Thermo Fisher Scientific Inc. (TMO) Q2 2025 Earnings Call Transcript
Positive7-23
The earnings call reveals strong financial performance with revenue and margin growth, positive biopharma trends, and strategic deals like the Sanofi acquisition. Despite challenges in China and academic sectors, management's optimism about long-term growth and share gains, alongside effective margin expansion strategies, suggests a positive outlook. The Q&A session reinforced confidence in growth, though some responses lacked detail. Overall, the company's strong position in biopharma and strategic initiatives indicate a likely positive stock price movement.
Thermo Fisher Scientific Inc. (TMO) BofA Securities 2025 Healthcare Conference (Transcript)
Neutral5-13
TMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
